The authors discuss the technique and evaluate the results of an aggressive surgical approach in patients with primarily unresectable colorectal liver metastases that were downstaged by chronomodulated chemotherapy.
Background
Resection is the best treatment of colorectal liver metastases, but it may be achieved in only 10% of patients. In the remaining 90%, survival is poor, even after partial response to chemotherapy. Little is known about the results of curative hepatectomy in patients whose metastases are downstaged by chemotherapy.
Patients and Methods
Fifty-three patients with colorectal liver metastases initially unresectable because of ill located (8) , large (8) , multinodular (24) lesions, or because of extrahepatic disease (13) were downstaged by a systemic chronomodulated chemotherapy associating 5-fluorouracil, folinic acid and Oxaliplatin to the point that operation could be performed. This consisted of a major hepatectomy in 37 patients and a minor resection in 16 . Associated procedures (including 5 two-stage hepatectomies and 3 pulmonary resections) were performed in 25 patients.
Results
There was no operative mortality. Complications occurred in 14 patients. The cumulative 3-and 5-year survival rates were 54% and 40% (according to the type of lesions: ill-located, 75% and 48%; large, 62% and 62%; multinodular, 54% and 40%; extrahepatic, 43% and 14%). Hepatic recurrence (34 patients, 64%) was amenable to repeat surgery in 15 cases.
Conclusions
Liver resection may be achieved in some previously unresectable patients with the help of an effective chemotherapy. The benefit in survival seems comparable to that obtained with primary liver resection (40% at 5 years). This therapeutic strategy involves a multimodal approach, including repeat hepatectomies and extrahepatic surgery.
509
Approximately half of all patients with colorectal cancer present at some stage with hepatic metastases.",2 Hepatic resection currently is the only form of treatment that offers a chance of long-term survival, with rates ranging from 25% to 39% reported in the literature. [3] [4] [5] [6] [7] However, using current indications for surgery, it is estimated that a curative operation can be performed in only 10% of all patients with colorectal metastases to the liver.",2 In the remaining patients-the majority-the prognosis is poor and symptomatic treatment or palliative chemotherapy are the only options available. Systemic chemotherapy using conventional cytotoxic agents, mainly 5-fluorouracil, is effective in some cases, but long-term survival is uniformly poor.8 Hepatic arterial chemotherapy has increased the clinical response rate, but its use has been limited by severe complications. 9 An incompletely explored benefit of chemotherapy in patients who respond favorably is that it may allow secondary resection of liver metastases in cases in which primary surgery had been considered impossible.
In this study, a group of patients with liver metastases who initially were refused for primary surgical resection responded to chemotherapy to the point that hepatectomy was reconsidered and performed. We present the results ofthis combined approach, with a special emphasis on the initial causes of unresectability, the methods used to facilitate liver resection, and the possible benefit in survival generated by secondary hepatectomy in this select group were treated with systemic chemotherapy, according to the description that follows. All were periodically reviewed with regard to modification ofthe criteria contraindicating primary resection. Of these, 53 responded to chemotherapy to a point that surgical resection was considered possible. These 53 patients represent the study population. There were 30 men and 23 women. Median age was 59 years (range, 32-84 years).
Protocol of Systemic Chemotherapy
All patients were registered in protocols aiming to evaluate the clinical relevance of chronomodulated intravenous infusion (through an implanted venous access port-Port-a-Cath, Pharmacia, Uppsala, Sweden) of 5- fluorouracil (700-1200 mg/m2/day), folinic acid (300 mg/m2/day) and oxaliplatin, a non-nephrotoxic platinum complex (25 mg/m2/day). Courses lasted 4 to 5 days and were repeated every 2 to 3 weeks. The administration of the drugs was done in ambulatory patients through a time/dose programmed multichannel pump (Intelliject, Aguettant, Lyon, France) according to the pattern shown in Figure 1 . The details and the toxicity of this chemotherapy regimen have been reported previously. 10"' Reconsideration of Liver Surgery All patients were followed up by oncologists and surgeons. Response was assessed every three treatment courses and defined according to previously reported criteria. 12 All radiologic investigations were reviewed by the same two radiologists highly specialized in hepatic imaging. Abdominal computed tomography scans were preferred for evaluation because they allowed better objective comparison and were less operator dependent than ultrasonography.
Hepatic resection was reconsidered periodically, along with the objective response to chemotherapy, and was attempted when technically possible and when potentially curative. To optimize the chances ofcurative resection, our policy was to perform the hepatectomy when the reduction in tumor size on repeated computed tomography and oftumor markers (carcinoembryonic antigen, carbohydrate antigen 19-9) had reached a plateau. Accordingly, the mean time under chemotherapy needed to downstage the disease so that secondary hepatectomy could be performed was approximately 8 months (Table 1) . When liver metastases were associated with pulmonary metastases and both were resectable, our policy was first to perform the liver resection and then, after two to three courses ofchemotherapy, the pulmonary resection. This approach seems logical because 
RESULTS

Surgical Procedures
Of the 53 patients, 16 (30%) underwent a minor hepatectomy (less than 3 segments) and 37 (70%) had a major hepatectomy (>3 segments). No difference in the extent of resection was noted between groups ( Table 3 .
Before Resection
Portal vein embolization was performed in five patients (9%). Two patients underwent rectal resection, one for anastomotic recurrence of the primary tumor and one for resection of the primary malignancy discovered concomitantly to the liver metastases.
At Time of Liver Resection
Cryosurgery was used as an adjunct to liver resection either to treat residual tumor nodules that could not be resected (4 patients) or to freeze the raw surface of the resection when the margin ofsecurity between the tumor and the normal liver was less than cm (2 patients). Associated extrahepatic surgery included one small bowel resection, one splenectomy, one partial resection of the diaphragm, and one desobstruction of the left portal branch occluded by a tumoral thrombus.
After Liver Resection
Five patients underwent the second stage of a twostage hepatectomy. Three patients underwent planned pulmonary resection ofsynchronous lung metastases (2-3 months).
Mortality
There was no intraoperative mortality or postoperative mortality within 2 months.
Complications
Fourteen complications were observed in the 53 patients (26%). There were 11 complications at the site of hepatectomy (5 fluid collections that resolved spontaneously, 3 infected fluid collections treated by percutaneous drainage, 1 reoperation for intra-abdominal bleeding, 2 transient biliary leaks) and 3 general complications (1 thrombosis of the upper vena cava in association with a central line, 1 renal failure in a diabetic patient, 1 septicemia).
Disease Recurrence After Liver Resection
The patterns of recurrence according to the initial causes ofunresectability are summarized in Table 4 . Hepatic recurrence was observed in 34 patients (66%) after a mean follow-up of 42 months. The rate of hepatic recurrence was lower in patients with metastases whose unresectability was related to extrahepatic disease (46%) than in the other groups (75% for large, 62% for ill-located, and 71% for multinodular tumors). A repeat hepatectomy-not considering two-stage hepatectomiescould be performed in 15 ofthe 34 patients (44%). A second resection could be performed more frequently in patients with large and multinodular tumors (37% and One patient with both abdominal and pulmonary recurrence.
42%, respectively) than in patients with ill-located tumors or patients with extrahepatic disease (12% and 8%, respectively). A third hepatectomy was performed in three patients with multinodular metastases. Extrahepatic recurrence developed in 25 patients (47%). Twelve patients had intra-abdominal recurrence (23%), seven of whom underwent reoperation and their recurrence were resected (5 8%). There were two anterior resections of the rectum, one total colectomy, one abdominoperineal excision, one small bowel resection, one lymphadenectomy, and one resection of the bile duct (invaded by a tumoral thrombus). Pulmonary metastases developed in 14 patients (26%), mainly in the group ofpatients with multinodular tumors (9 patients) or with extrahepatic disease (3 patients). A pulmonary resection could be performed in 6 ofthe 14 patients with lung metastases (43%), and 4 patients underwent repeat pulmonary resections. Overall, among the 53 patients of the study, there were 73 hepatectomies, 13 lung resections, and 29 associated surgical procedures either before hepatectomy (5 portal embolization procedures), at time of liver resection (13 associated hepatic and 4 extrahepatic procedures) or after liver resection (7 abdominal procedures).
Patient Outcome
Patient outcome is summarized in Table 5 . Overall patient survival for the 53 patients is 54% and 40% at 3 and 5 years, respectively (Fig. 6) . The survival rate at 3 and 5 years is 62% in patients with large tumors and 75% in patients with ill-located tumors (Figs. 7A-7B ). It was higher in these two groups compared with patients with multinodular tumors (44%-37%; Fig. 7C ) or extrahepatic disease (43%-14%; Fig. 7D ). Twenty-seven patients died after a mean follow-up of 24 months, mainly from recurrence of liver metastases (85%); 26 patients currently are alive with a mean follow-up of 42 months. Of these, 19 are disease free, representing 36% of the series (Table 5) . Ofthe 34 patients with hepatic recurrence, 12 (35%) currently are disease free after repeat hepatectomy; of the 26 patients with extrahepatic recurrence, 2 (8%) currently are disease free after repeat surgery at a mean follow-up of 46 months (range, 25-85 months).
DISCUSSION
We present the results of potentially curative secondary hepatectomy on 53 patients whose primarily unresectable colorectal liver metastases were downstaged by chemotherapy. The fact that patients with liver metastases initially considered unsuitable for radical surgery can undergo potentially curative surgery after chemotherapy is a recent concept in the management of these patients. This combined approach has been reported recently in smaller series of patients after other chemotherapeutic protocols.17"8 Independently from the type of chemotherapy, the main point of our study and of others' is that there is hope for a curative treatment in a group of patients generally considered incurable. Our study emphasizes the importance of reconsidering liver resection in patients who are at first not candidates for primary surgical excision, but who respond well to chemotherapy. Furthermore, it defines a new role for systemic chemotherapy when used in patients in whom the disease is judged too advanced for primary hepatic surgery.
Among the patients with colorectal liver metastases, resection is the only treatment offering a chance of long- Other modalities of administration, such it is uncommon that a as regional intra-arterial chemotherapy have obtained a considered beyond op-higher response rate in selected patients, but their more a second chance for re-widespread use is hampered by their increased toxicity h unresectable hepatic and incidence of complications.9 Survival is increased r is poor, ranging from moderately but not significantly as compared with sysIs of the liver are in-temic chemotherapy.26'28 tic treatment and palliIn this study, we used chronomodulated chemothercommon modalities of apy with 5-fluorouracil, folinic acid, and oxaliplatin. ipy is used most fre-With this mode of administration, the doses of medica--fluorouracil, with re-tion that can be given without toxic side effects are larger 5% and 25%.621 More than those usually administered when these drugs are Logic modulation of 5-given as short-term or as fixed-rate infusions.'0 " Furartial clinical responses thermore, the chemotherapy protocol was administered ,22-24 and some studies in an outpatient setting, minimizing the discomfort to il with chemotherapy the patients. A high response rate was observed, which allowed a subsequent resection in 53 of 330 patients initially considered unresectable by our surgical team (16%).
Surgical treatment ofthese patients requires all the armamentarium of liver surgery techniques. Intraoperative ultrasound was an indispensable tool for a complete diagnosis of the tumoral disease and for planning the 54% adapted surgical procedure. The objective of liver resection was to remove all tumor tissue, with a margin of 40% security of at least 1 cm. However, in cases in which the tumors arrived in contact with the main vessels, the margins had to be more limited. In multinodular tumors, the margins also were limited by the number of nodules and their proximity to main vascular structures In case of recurrence, independent of the site, our policy was to propose a new resection when it was technically possible and it could aim at removing all macroscopic disease. Accordingly, 15 of the 34 patients with hepatic recurrence in the series underwent a repeat hepatectomy, and 7 of 12 patients with abdominal recurrence and 10 of 14 patients with pulmonary recurrence were submitted secondarily to a new resection.
This attitude, associated with chemotherapy, allowed disease-free survival in more than one third of patients (36%). It may be argued that this proportion represents a minority of patients with regard to the aggressiveness of our strategy. However, these results are comparable with those observed after conventional liver resection ofcolorectal metastases.3-7 The criticism could be made that our policy of treating with chemotherapy all patients with unresectable colorectal metastases casts too wide a net for the small number of patients in whom downstaging occurs and who can benefit from secondary resections. Currently, it is impossible to predict which individual will respond and which will not, and further work is needed in this direction. It also has to be added that systemic chemotherapy is accepted as the standard treatment in our country for patients with unresectable colorectal liver metastases, whether they are considered for secondary surgery or not, and most patients are receiving it regardless of whether secondary resections are considered. Further effort also is needed to obtain still more effective chemotherapeutic protocols, such as intensified chronomodulated chemotherapy,3' to increase the proportion of patients who can be resected secondarily and to lower the high incidence of recurrence seen after surgery. One of the dicta that I have adhered to in the past, and most of us have, when considering the possibility ofresection of metastatic tumors within the liver, including those originating in the colon and rectum, is that it is appropriate if not imperative to obviate a needless celiotomy. To this end we have adopted the use of hepatic arterial and portographic computed tomography (CT) scans and found them to be the most effective.
Our decisions have been based on the studies that were put together by Dr. Hughes-this is a cumulative series, reported first in 1986, substantiated by subsequent addition of data-a 5-year survival rate of 33% and a 5-year disease-free survival rate of 25% for resection of colon and rectal lesions metastatic to the liver. In our own personal experience with slightly more than 100 cases, the figures are mirrored. It is approximately a 30% 5-year disease-free survival rate, as evidenced by normal CT scan results and a normal carcinoembryonic antigen level.
I must stress that this multicenter series and our own personal series focus solely on the optimal patients with no evidence of extrahepatic disease, all lesions relatively contiguous, limited to four in number, and all within a segment ofthe liver that can be readily excised. We thank Henri Bismuth and his colleagues for the opportunity to review their manuscript. They have presented 434 patients with colorectal liver metastases in whom they initially operated on 104, or 24%. By routinely treating the remaining 330 patients with infusional chemotherapy, they were able to select an additional 53 patients, or 12% of the original group, for surgical therapy. By using the entire armamentarium of surgical therapies, they were able to achieve a 40% 5-year survival rate in these 53 patients.
First of all, I would like to point out that this strategy is similar to the multimodality neoadjuvant approach that has been used and reported by Dr. Sitzman from our hospital in patients with hepatocellular carcinoma, with surprisingly good results.
